We scan new podcasts and send you the top 5 insights daily.
John Chatzko said the fourth adjuvant sample was not readily interpretable because of patient attrition, possible test failures, and schedule differences: EV+Pembro was drawn at adjuvant cycle eight day one, gem/cis at surveillance. Tom warned that aspirational serial-testing designs will lose patients, as even INVIGOR-11 struggled to retain them.
The INVIGOR-11 trial data should be applied carefully. A positive ctDNA result post-surgery indicates when to *initiate* adjuvant immunotherapy. However, if a patient on neoadjuvant therapy becomes ctDNA-negative, this signals treatment efficacy and is a reason to *continue* the planned course, not a justification for stopping it early.
While trials like IMvigor011 show ctDNA can guide adjuvant immunotherapy after surgery, this data may not apply to the new standard of care. With neoadjuvant EV/pembrolizumab becoming prevalent, the prognostic and predictive value of post-operative ctDNA is now unknown, requiring new prospective studies.
For patients with aggressive, rapidly progressing disease, clinicians use serial ctDNA monitoring between scheduled imaging scans. A rising ctDNA tumor fraction can serve as an early warning sign of treatment failure, allowing for quicker therapeutic pivots before the cancer grows significantly.
Tom said no pre-surgery ctDNA-positive patient achieved pCR in EV304 or Niagara. Among ctDNA-negative patients, pCR was 75% with EV+Pembro but roughly 50-50 with chemotherapy. That makes bladder-sparing risky while ctDNA remains positive; the test is not a green light for less local therapy.
Despite the promise of liquid biopsies for monitoring, the SERENA-6 trial revealed a significant challenge: fewer than 10% of screened patients developed a detectable ESR1 mutation. This low yield questions the efficiency and broad applicability of this serial screening strategy to guide treatment changes.
The TRACK-ER study reveals a critical weakness of tumor-informed ctDNA monitoring: a 16% failure rate. This occurs when there's insufficient tumor tissue or too few personalized variants to track. This technical barrier poses a significant obstacle to widespread clinical implementation, highlighting the need for more robust or alternative assay technologies for all patients to benefit.
A critical warning for clinicians: data showing that ctDNA-negative patients can skip *adjuvant* therapy (InVigor011) should not be extrapolated to the *neoadjuvant* setting. Stopping the post-operative portion of a perioperative EV-Pembro regimen based on a negative ctDNA result is unsupported by data and risks under-treating patients.
Tumor-informed ctDNA assays, which require a tissue sample, are highly sensitive and well-suited for the adjuvant setting where tissue is available and time is less critical. In the metastatic setting, logistical challenges and the need for faster results make this approach less practical.
While a positive ctDNA test clearly signals the need for adjuvant therapy, a negative result is less actionable for deciding initial treatment. The key prognostic value comes from being *serially* undetectable over time, information that is not available when the immediate post-surgery treatment decision must be made.
Tom noted 24-month EFS was 94% in EV+Pembro patients who were ctDNA-negative at baseline and stayed negative, but John Chatzko cautioned that about a quarter of pre-surgery ctDNA-negative EV+Pembro patients still lacked pCR. They favored randomized de-escalation trials over routine treatment reduction; the high survival is real, but causal attribution is not.